The Global Oncology Drugs Market to Surpass USD 368 Billion

New York, USA, Oct. 18, 2022 (GLOBE NEWSWIRE) — The Global Oncology Drugs Market to Surpass USD 368 Billion by 2027, Assesses DelveInsight

The oncology drugs market is expected to grow due to the rising prevalence of cancers such as lung cancer, as well as the impact of other factors such as the aging population. Furthermore, the growing interest in developing targeted therapies to capitalize on advances in precision medicine is a significant factor driving the remarkable growth of the oncology drugs market.

DelveInsight’s Oncology Drugs Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, oncology drugs market drivers, barriers, and trends, and key oncology drugs companies in the market.

Key Takeaways from the Oncology Drugs Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global oncology drugs market during the forecast period.  
• Notable oncology drugs companies with various oncology pipeline drugs include GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, and others.
• In October 15, 2021, the FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
• In August 2021, Bristol Myers Squibbs received conditional marketing authorization for Abecma (idecabtagene vicleucel) from the European Commission to treat adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor…